Clinical Trial Update: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Pasireotide LAR and Everolimus alone or in combination for neuroendocrine carcinoma of the lung and thymus has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma of the Lung
• Neuroendocrine Carcinoma of the Thymus

Drugs mentioned

• Everolimus (everolimus)
• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neuroendocrine Carcinoma of the Lung and Thymus | Phase 2 | Status: COMPLETED | Results posted: 2021-04-02